Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues

H. Takeuchi, H. Baba, S. Inutsuka, I. Takahashi, H. Kusumoto, Y. Maehara, K. Sugimachi

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Abstract

The chemosensitivity of 43 human sarcoma tissues, including 18 osteosarcomas, 16 leiomyosarcomas and 9 liposarcomas was compared with that of 28 adenocarcinomas of the stomach using the in vitro succinate dehydrogenase inhibition (SDI) test. These tissues were exposed for 3 days to each antitumor drug including adriamycin (ADM), 5-fluorouracil (5-FU), mitomycin C (MMC), cisplatin (CDDP), aclacinomycin A (ACR) and carboquone (CQ), then the cell viability was estimated based on the succinate dehydrogenase (SD) activity determined using [3-(4,5-dimethyl-2-thiazolyl) -2,5-diphenyl-2H tetrazolium bromide] (MTT). SD activity was significantly lower in the osteosarcoma as compared to that in the adenocarcinoma for ADM, MMC, CDDP, ACR and CQ (p < 0.01) and was higher for ADM (p < 0.05) in cases of leiomyosarcoma and for CDDP (p < 0.01) and ACR (p < 0.05) in cases of liposarcoma. The sensitivity rate was higher in osteosarcoma than in adenocarcinoma for ADM, MMC and CDDP. These findings suggest that patients with osteosarcoma will probably show a fairly good response to antitumor drugs and that when liposarcoma or leiomyosarcoma tumors show resistance to antitumor drugs then resection at the time of initial exploration and combined modalities, including radiation and hyperthemia should be considered.

Original languageEnglish
Pages (from-to)169-171
Number of pages3
JournalAnticancer research
Volume14
Issue number1 A
Publication statusPublished - 1994

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues'. Together they form a unique fingerprint.

Cite this